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Help for recurrent bacterial 
vaginosis
Suggest that women who are plagued by recurrent 
episodes of BV try vaginal probiotic capsules. 
PRACTICE CHANGER
Recommend high-dose vaginal probiotic cap-
sules to prevent recurrent bacterial vaginosis.1
STRENGTH OF RECOMMENDATION
B: Based on a single high-quality randomized 
controlled trial (RCT)
Ya W, Reifer C, Miller LE. Effi  cacy of vaginal probiotic capsules for 
recurrent bacterial vaginosis: a double-blind, randomized, placebo-
controlled study. Am J Obstet Gynecol. 2010;203:120.e1-120.e6.
ILLUSTRATIVE CASE
A 26-year-old nonsmoking woman with a single 
sexual partner comes in with the second bout of 
bacterial vaginosis (BV) she’s had this year. What 
can you give her to prevent a recurrence? 
Bacterial vaginosis is the most com-mon cause of vaginal discharge in women, responsible for 40% to 50% of 
clinical cases. Among American women ages 
14 to 49, the general prevalence—including 
asymptomatic cases—is close to 30%.2
Recurrence rate, as well as prevalence, 
is high
BV is caused by a shift in vaginal fl ora from 
hydrogen peroxide-producing Lactobacillus 
species to anaerobes that raise the vaginal 
pH. Multiple species of anaerobic bacteria 
are implicated. Th e drug of choice for treat-
ment of BV continues to be metronidazole, 
a drug prescribed for the past 45 years with 
minimal resistance.3 However, there is grow-
ing resistance among Bacteroides species. 
Oral or intravaginal clindamycin is another 
option for treating BV.4
Even with the use of metronidazole, re-
currence is common—with as many as 50% 
of symptomatic infections recurring within a 
year.5 A randomized, double-blind placebo-
controlled trial published in 2006 compared 
the results of 1 week of oral metronidazole 
(500 mg) twice daily plus 30 days of oral pro-
biotics vs the same dose and duration of met-
ronidazole plus 30 days of placebo.6 Th e rate 
of recurrence at the end of 1 month was 12% 
in the antibiotic/probiotic group vs 60% in 
the antibiotic/placebo group. 
Th e RCT reviewed here evaluated the ef-
fectiveness of a vaginal probiotic capsule in 
preventing recurrent BV.
STUDY SUMMARY
Probiotic use lowered 
recurrence rate
Ya et al enrolled 120 Chinese women with 
a history of recurrent BV in a double-blind 
RCT.1 To be eligible, women had to be healthy, 
between the ages of 18 and 55, and free from 
BV (but have a history of ≥2 episodes in the 
previous year). Th ey also could not have had 
any antibiotic treatment within a week of 
study participation, and had to be willing to 
refrain from using other intravaginal prod-
ucts during the course of the study. 
Th e researchers excluded women who 
were found to have other causes of vulvovagi-
nitis or urogenital infection within 21 days 
of participation, were pregnant or lactating, 
ate yogurt or fermented milk on a daily basis, 
were allergic to study product ingredients, or 
were immunosuppressed. 
Bacterial 
vaginosis was 
diagnosed in 
15.8% of women 
in the probiotic 
group and 45% 
in the control 
group.
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Participants were assigned to either BV 
prophylaxis with the vaginal probiotic cap-
sule Probaclac Vaginal (a lactose capsule 
containing 8 billion colony-forming units 
[CFUs] of Lactobacillus rhamnosus, L aci-
dophilus, and Streptococcus thermophilus) 
(n=58) or a placebo capsule containing lac-
tose alone (n=62). Both groups had similar 
baseline characteristics; most of the women 
were nonsmokers who had had either one 
sexual partner or no partners within the pre-
vious year. 
After a baseline evaluation, the par-
ticipants used the vaginal capsules daily for 
7 days, skipped usage for 7 days, and then 
used them again for a fi nal 7 days. Th e wom-
en then returned for follow-up visits at 30 
and 60 days after treatment began for the 
collection of vaginal swabs, an assessment of 
vaginal fl ora, and a report of adverse events. 
Researchers also contacted them by phone 
roughly 11 months after treatment started 
to ask about BV symptoms or diagnosis after 
treatment.
Th e primary end point was the diagnosis 
in the fi rst 2 months of BV using Amsel criteria: 
the presence of thin, grey-white homogenous 
discharge coating the vaginal walls; vaginal 
pH >4.5; a positive whiff -amine test (pres-
ence of “fi sh smell” with potassium hydroxide 
[KOH] or KOH prep); and the presence of clue 
cells on normal saline wet mount.7 
Th is end point—based on the presence 
of 3 of the 4 criteria—was reached in 15.8% of 
women in the probiotic group and 45% in the 
control group (odds ratio [OR]=0.23; 95% con-
fi dence interval [CI], 0.10-0.55; P<.001), with a 
number needed to treat (NNT) of 3.4. 
A secondary end point was the confi rmed 
diagnosis of BV between 2 and 11 months; 
only 10.6% of women in the probiotic group 
and 27.7% of women in the control group had 
confi rmed BV (OR=0.31, 95% CI, 0.11-0.93; 
P=.04), with an NNT of 5.8. No adverse advents 
were reported.
WHAT’S NEW
A new use for probiotics 
is established 
Th is trial supports the use of probiotic vaginal 
capsules in the prevention of recurrent BV. 
We found the specifi c formulation (Probaclac 
Vaginal) that was tested in this RCT on an 
online natural health site (http://www.lady
tobaby.com/show.php?item=219). Th is Web 
site sells Probaclac Vaginal at a cost of $28 for 
10 capsules. A full course of a week’s treat-
ment, repeated once, would cost approxi-
mately $56.
CAVEATS
Will other formulations work? 
Th is study was funded by the makers of Pro-
baclac Vaginal, so we will be watching for 
independent replication of these fi ndings 
in other populations. Th e vaginal probiotic 
tested had 80 times the current recommend-
ed concentration of lactobacilli required to 
restore and maintain normal vaginal fl ora, 
so we are unsure as to whether less con-
centrated formulations would be equally 
eff ective. 
Probiotic formulations diff er widely, 
although some are similar to the species/
concentration used in Probaclac Vaginal, 
including LactoViden ID by Metagenics 
(http://www.metagenics.com/products/a-
z-products-list/LactoViden-ID), with 15 
billion CFUs, and Th erbiotic by Klaire Labs 
(http://www.klaire.com/prod/proddetail.
asp?id=V775-06-CN), with 25 billion CFUs. 
Also, this intervention has not been test-
ed in populations outside of China, in heavy 
smokers, or in women with more than one 
sexual partner, so there is a small risk that 
these fi ndings may not be confi rmed in sub-
sequent RCTs or may not be generalizable 
to other populations. Nonetheless, we think 
the potential benefi t outweighs any possible 
harm, and we will be watching for studies 
that confi rm or challenge these fi ndings. 
CHALLENGES TO IMPLEMENTATION
Finding the right probiotic 
Th e brand used in the study is available only 
on the Web, which may be diffi  cult for some 
patients to access, and some patients will fi nd 
the probiotic to be fairly expensive. In addi-
tion, other brands of probiotics may not be 
available as a vaginal capsule with applicator. 
It should be noted, though, that it is possible 
This intervention 
has not been 
tested outside 
of China, or in 
women with 
more than one 
sexual partner, 
so fi ndings 
may not be 
generalizable. 
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to use an applicator to insert an oral probiotic 
capsule into the vagina.                 JFP
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What do I need 
        to know about gout?
This CME supplement and supporting webcast discuss: 
•   The risk factors and comorbidities that contribute to and exacerbate 
acute gout fl ares
•  Criteria for establishing a diagnosis of gout 
•   How to establish goals for achieving, sustaining, and monitoring clinically 
meaningful urate lowering 
•   Means for optimizing patient adherence to long-term 
urate-lowering treatment
The supplement and audiocast were submitted by the Primary Care Education Consortium 
and supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
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